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Editor’s key points
† Translating findings from pre-clinical models to
effective clinical therapy has had limited
success.
† Studying peripheral mechanisms directly in
human pain states may avoid these problems.
† Evidence from clinical studies emphasizes the
importance of peripheral drive in maintaining
chronic pain.
† A number of peripheral mediators, including
monoclonal antibodies, may have potential as
novel analgesics.
Summary. Research efforts over the past two decades have helped us
better understand the biological mechanisms that lead to chronic
pain. Despite this, there has been limited progress in developing novel
analgesics to treat sufferers of persistent pain conditions, who may
account for as many as one-fifth of the population. A re-evaluation of
the strategies used to discover pain-relieving drugs is needed to meet
this widespread clinical need. Here, we discuss the merits of pursuing
peripherally acting pain mediators. We review the significant clinical
evidence that neuronal activity from the periphery is a major
contributor to painful symptom production and that peripheral
mediators play a substantial role in this aberrant nociceptor activity.
We discuss the clinical benefits of blocking individual known mediators
and describe our own approach to identify novel mediators.
Keywords: analgesia; chronic pain; nociception
As several articles in this special edition point out, there is an
urgent need to develop new treatments for pain. The reason,
of course, is that chronic pain affects large numbers of people—
most estimates put the figure at close to 20%—and a consider-
able proportion of these do not get adequate pain relief from
existing therapies.1 2 It is not that these therapies do not show
efficacy. They do, although this efficacy may be limited in scope
and have significant and dose-limiting side-effects.
In response, the research community has not been idle. The
last two decades has seen a tremendous jump in understand-
ing of the pathophysiological mechanisms in play in persistent
pain states. Several technical advances have driven this
process, ranging from the now ubiquitous use of transgenic
mouse technologies to study the role of particular genes
expressed in particular cells, through to the increasingly
sophisticated analysis of higher and higher resolution brain
imaging studies and, more recently, the ability to undertake
genome wide sequencing in studies of transcriptional expres-
sion and genetic variants.
These research efforts have identified a myriad of potentially
important targets for developing novel therapies using cogni-
tive, surgical (e.g. spinal cord stimulators) and pharmacological
strategies. The latter (in common with drug development across
anumberofdiseaseareas)havenotbeengreatlysuccessfulwith
almost no new registrations for analgesic drugs in the last
decade. This article will explore the idea that one of the most
fruitful areas for drug development lies in identifying novel per-
ipheral pain mediators. The thrust of the argument is that most
persistent pain states are driven or maintained by abnormal ac-
tivity in peripheral nociceptors and that targeting single media-
tors can, in appropriate circumstances, offer considerable
analgesic efficacy, without complications of central side-effects.
Most chronic pain depends on a peripheral
drive
Much effort has been concentrated in recent years on elucidat-
ing the underlying mechanisms contributing to persistent pain
states. Some conditions (e.g. fibromyalgia) may be the result of
plastic changes within the central nervous system. To add
further complication, the exact origins of persistent pain can
be difficult to identify in situations where pain is referred,
e.g. conditions of visceral hypersensitivity. However, for the
majority of chronic pain conditions, there is now a large body
of evidence which strongly suggests that activity from the per-
iphery is essential, not only to initiate but also to maintain,
painful symptoms. Multiple lines of evidence from clinical
studies, where block of peripheral nociceptive input has been
shown to effectively relieve chronic pain, are considered here.
Joint replacement
Some of the most compelling evidence confirming the neces-
sity for peripheral drive comes from clinical observations
following the replacement of persistently painful joints or
removal of diseased tissue in the case of osteoarthritis (OA).
It has been reported that a large number of patients (up to
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73%; Table 1) who have undergone joint replacement surgery
show complete resolution of painful symptoms in the following
2–7 yr.3 4 Of the patients who still experience pain, 70–80%
reported significantly reduced pain scores compared with pre-
operative ratings. The persistence of pain in some patients
after the removal of the affected joint may be suggestive of
an ongoing central component, although it is possible that
some are in fact experiencing moderate to severe persistent
post-surgical pain, a phenomenon that occurs in a significant
number of surgical operations.5
Pain is a defining feature of OA, with the majority of sufferers
experiencing their most severe symptoms during ambulatory
movements with lesser pain at rest.4 The levels and the dur-
ation of the noxious input during movement in these patients
suggests that central sensitization could be responsible for
the chronic nature of their pain. However, abnormal pain sen-
sation is lost in the majority of OA patients when the diseased
peripheral tissue is removed, even taking into account post-
surgical complications. This suggests that the pain is either per-
ipherally driven, most likely because of aberrant afferent input
as a result of elevated pro-inflammatory mediators, or that
spinal cord plasticity requires continued peripheral pathology
in order to be maintained.
Local steroids
Glucocorticoids are potent anti-inflammatory and immuno-
suppressive agents which exert their actions via glucocorticoid
receptors on immune cells.6 They are often administered to
patients with arthritis locally (e.g. intra-articularly) to limit
the large side-effect profiles of these drugs when given system-
ically. Interestingly, the most beneficial effect of such local de-
livery is the reduction of pain associated with the disease. Pain
relief from glucocorticoid treatment hasbeen reportedto last for
up to 3 weeks in OA and 2 months in rheumatoid arthritis (RA).7
Although the immunosuppressive nature of these agents
prevent their long-term use, the efficacy of local glucocorticoids
provides robust evidence for a strong peripheral component in
chronic pain states associated with inflammation, most likely
by inhibiting pro-inflammatory mediator release.
Lidocaine patch/regional anaesthesia
During the transmission of normal pain signals, action poten-
tials are generated in nociceptors via the voltage gated
sodium channels (VGSCs) whose action can be blocked using
local anaesthetics (e.g. lidocaine).8 Following peripheral
nerve injury, such channels accumulate at the site of injury
where they are thought to be responsible for the generation
of ectopic nociceptor activity and subsequent sensations of
spontaneous pain.9 These ectopic discharges can also be
prevented using lidocaine.10 In addition, the activity of VGSCs
can be modulated by inflammatory mediators known to
cause nociceptor sensitization [e.g. prostaglandin E2
(PGE2)].11 Systemic administration of lidocaine has provided
analgesia to patients with peripheral neuropathy in clinical
trials,12 although this could be because of central actions.13
Post-herpetic neuralgia is a painful neuropathic condition
whereby the efficacy of locally applied lidocaine can be
readily assessed because of the localization of pain to the
area of original pathology (shingles). Here, the topical applica-
tion of 5% lidocaine (as a gel or patch) has been demonstrated
to significantly relieve pain and reduce pain intensity with afast
onset (within 30 min) and lasting for the duration of drug appli-
cation.14 15 Furthermore, lidocaine has proved more efficacious
at relieving pain in post-herpetic neuralgia when compared
with treatment with pregabalin, a centrally acting analgesic.16
Additionally, studies have also shown that lidocaine patches
provide highly effective pain relief in patients with various
painful neuropathies.17 Even in persistent pain states where
symptoms are largely thought to be a consequence of
central sensitization (e.g. complex regional pain syndrome),
the use of peripheral lidocaine to block peripheral input into
the spinal cord can cause central processing to revert to
normal, abolishing the symptoms for the duration of the
block.18 Such observations suggest that peripheral drive
could be crucial in the maintenance of chronic pain in some
patients.
Capsaicin patch
Capsaicin is a potent agonist for transient receptor potential
vanilloid (TRPV1) channels, which are expressed at the periph-
eral terminals of C-fibre nociceptors. The application of capsa-
icin to the skin causes burning pain and hyperalgesia;19 20
although, conversely, high concentrations desensitize TRPV1
and can cause selective C-fibre terminal degeneration
leading to increased heat and mechanical pain thresholds.21 22
Administration of daily topical capsaicin for up to 8 weeks
can significantly reduce pain in neuropathic pain patients.23
Additionally, single applications of high-dose capsaicin
patches have provided significant analgesia in post-herpetic
neuralgia and neuropathy associated with human immuno-
deficiency virus 1 (HIV-1).24 Of course, one problem with
these trials is the difficulty in blinding patients to treatment.
Nonetheless, because all the actions of capsaicin appear to
be mediated via a direct action on nociceptors, these data
demonstrate the importance of peripheral drive.
Table 1 Evidence that chronic joint pain is largely driven from the
periphery. The majority of patients who undergo total knee or hip
replacement report total resolution of their painful symptoms,
assessed using the Western Ontario and McMasters Universities
Arthritis Index score, after surgery. The failure to eliminate pain in
the remainder of patients may be because of the development of
post-surgical pain, which can be a result of damage to peripheral
nerves during surgery. Data sourced from3
Total knee
replacement
(n-632)
Total hip
replacement
(n-662)
No pain 56% 73%
Mild pain 12% 9%
Moderate pain 17% 11%
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Use of peripherally targeted biologics
In recent years, the emerging use of biologics (e.g. functional
blocking antibodies against inflammatory mediators), suggests
that the activity of individual mediators could be targeted to
treat painful conditions. Such treatments are usually proteins
which do not cross the blood–brain barrier (BBB); therefore,
they must be exerting their beneficial effects in the periphery.
Examples of these will be discussed further in the following
section.
Known peripheral mediators
The evidence presented in the previous section begs the ques-
tion of what underlies abnormal nociceptor activity in persist-
ent pain states. In some circumstances, changes intrinsic to
the nerve fibre themselves may be responsible. One example
would be ectopic impulses that develop in some neuropathic
conditions that are likely to be secondary to alterations in the
expression of ion channels in these neurones.25 Another puta-
tive example, is the sensitization of channels (e.g. TRPV1) that
might be sufficient to allow nociceptors to fire at normal body
temperature.26 However, in both these cases, something hasto
initiate the change and that is likely to be a chemical signal
initiated from the damaged tissues. Where nociceptors have
normal properties but are simply activated, again the reason
in nearly all cases will be chemical signals liberated by the
affected peripheral tissues. These chemical mediators are
prime targets for analgesic drug development because, as
reviewed above, blocking the peripheral drive has, when it is
possible to do this, proved to be an effective way of relieving
pain in some individuals. Several such peripheral pain media-
tors have already been identified, as we briefly review below.
Prostanoids
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely
used and are the first line of treatment for many persistent
pain states. Their mechanism of action was first described by
Vane in 1971 who showed that they inhibit the enzyme
cyclooxygenase (COX) and prevent the subsequent production
of prostanoids (lipid mediators) which are responsible for the
inflammatory and algesic effects.27 A major site of action of
NSAIDS is known to be in peripheral tissue,28 although there
is additionally good experimental evidence for a central
action.29 When NSAIDs are given systemically, it is not
certain where their site of action is as they can cross the
BBB.30 However, NSAIDs can be applied topically. In this case,
plasma concentrations remain far below those achieved after
systemic delivery, clearly indicating a local site of drug
action.31 In addition, much greater tissue concentrations can
be achieved compared with systemic delivery32 and, in pre-
clinical models, topical application of NSAIDs can attenuate in-
flammatory hypersensitivity.33 Pre-clinical work has also
demonstrated that pro-inflammatory prostaglandins (e.g.
PGE2) can sensitize nociceptors, produce pain-like behaviour
when injected peripherally34–37 and are over-expressed in
hypersensitive tissue areas after inflammation.38
NSAIDs are used clinically to treat chronic musculoskeletal
pain.39 Meta-analysis of 25 randomized, double-blind,
placebo-controlled clinical trials in patients suffering from
chronic musculoskeletal pain including but not exclusive to
OA, found that topical NSAID treatment was significantly ef-
fective in reducing pain scores. In addition, in the few trials
which compared systemic and topical treatment, albeit with
different compounds, no differencewas found in the successful
reduction of pain in patients.39 This analysis also reveals that
the magnitude of analgesia offered by NSAIDS is often
limited by dose-limiting side-effects and intrinsic limited effi-
cacy. These findings argue for an important role of other med-
iators not regulated by COX activity.
Tumour necrosis factor-alpha
The use of function-blocking antibodies highlights the import-
ance that individual peripheral mediators can play in persistent
pain states as these are large proteins which do not cross the
BBB to a significant degree. Inhibitors of tumour necrosis
factor-alpha (TNFa) have been used successfully to treat in-
flammatory diseases, most prominently RA. This autoimmune
disease is commonly associated with persistent pain and it is
well known that these biologics help to reduce the symptoms
of RA. For example, the assessment of two anti-TNFa agents
(Etancerpt and Adalimumab) over a 3-month period found
that they significantly improved a variety of RA patients
assessed in multiple ways; one of the of the most prominent
improvements was in the reduction of pain.40 This effect is
also seen in patients where the disease is well established
(mean duration 12.5 yr).41 It is claimed that some TNFa block-
ers may be particularly effective in reducing pain scores.42
As anti-TNFa drugs are disease modifying, it is difficult to
know whether the pain relief is a primary or a secondary
event. Some authors have argued that the time course of anal-
gesic onset precedes that of disease modification (suggesting
a primary analgesic action)43 but this is not supported by some
studies. The analgesic effects of TNFa inhibitors are not limited
to RA)44 but equally these agents are not broadly acting
analgesics.
Interleukin 1b
As with TNFa inhibitors, the analgesic ability of interleukin 1b
(IL1b) block is well known. Anakinra is a recombinant protein
of the naturally occurring IL1 receptor antagonist and binds
to IL1 receptors to prevent their activation by IL1b. In numer-
ous clinical trials, this drug has proved effective in the relief of
pain in RA.45 In a pilot study, another IL1b inhibitor (Rilonacept)
was used to treat patients with chronic gouty arthritis. Two
weeks after Rilonacept treatment, visual analogue scale
(VAS) pain scores were significantly reduced compared with
placebo and, after 6 weeks, half of the patients reported a
75% improvement in their pain ratings.46 The same caveats
apply as to whether the analgesia is a primary or a secondary
phenomenon.
BJA Richards and McMahon
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Nerve growth factor
A considerable bodyof pre-clinical data suggeststhatperipher-
ally produced nerve growth factor (NGF) may be an important
pain mediator47 (for review see48). These data prompted the
trial of several anti-NGFantibodies by different pharmaceutical
companies. The major focus of these trials has been in OA pain
and it appears the different antibodies have similar effects).49
Some of the trial data have been published; for example,
Figure 1 is taken from a large phase II trial of Tanezumab in
OA pain.50 The antibody was given twice, 8 weeks apart at dif-
ferent doses. Patients entered the trial with an average VAS
rating of 71 (100-point scale). The figure shows the improve-
ment in VAS ratings. It is clear that this drug has unparalleled
efficacy in treating OA pain, with the highest doses resulting
in an average VAS reduction amounting to 50%. The Food
and Drug Administration stopped these trials in 2010
because of the need for earlier than expected joint replace-
ment in a small number of patients. The ban on trials was
lifted last year and it is yet to be seen whether rapidly
progressing OA associated with the early trials will limit or
even prevent the use of this approach. However, the data
demonstrate that targeting a single peripheral mediator can
be extremely effective in treating pain, and pain that, in
some cases, is very long lasting and associated with numerous
co-morbidities. In smaller trials, anti-NGF treatment has also
been found to have efficacy in conditions often refractory to
other analgesics [e.g. low back pain51 and bladder pain
syndrome (formally interstitial cystitis)].52 These findings are
important as it is sometimes said that the ‘inflammatory
soup’ present in manydisease states will limit the effectiveness
of strategies targeting a single mediator. This is clearly not the
case.
Other mediators
There are a large number of other mediators suggested by pre-
clinical work, including adenosine triphosphate (acting on P2X
receptors expressed on nociceptors), bradykinin, and several
chemokines. However, because these have not yet been
demonstrated to show efficacy in the clinic they fall outside
the scope of this review. The interested reader is directed to a
review by McMahon and colleagues.53
Finding novel pain mediators
Most of the research aimed at increasing understanding of pain
mechanisms has been undertaken using animal models. That
is, the pain state of interest, or a surrogate for it, is created in a
laboratory animal, usually rodent. Mechanisms can then be
studied at any of a number of levels including behavioural
responses, anatomy, electrophysiology and, more recently,
measures of gene expression of function. These animal
models have some clear advantages, such as the ability to
make similar lesions at a given developmental age of genetic-
ally similar animals. A wealth of invasive experiments is
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Fig1 Targeting pain individual peripheral mediators can relieve pain. The figure shows datafrom a phase II trial using Tanezumab to neutralize NGF
in patients with painful OA. The pain experienced while walking was assessed on a 100 point VAS scale. Tanezumab (10–200 mg kg21) or placebo
was given at the start of the study and at Week 8, and the change in VAS score from baseline was calculated. A decrease in VAS score is indicative
reduced pain. Patients entering the study had an average VAS rating of 71. Data from50. Reprinted with permission from Massachusetts Medical
Society.
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possible. However, there has recently been considerable
debate about the usefulness of this approach, driven largely
by the very low conversion of mechanisms identified in pre-
clinical models to effective new therapies in the clinic. As the
same problems of translation have been found, not only in re-
lation to pain, but in nearly all therapeutic areas, it is not clear
whether putative failings in animal models are particularly a
problem for pain research. However, it has led to renewed
efforts to start, not with animal models, but with human
disease states. The search for novel peripheral pain mediators
is entirely suited to this approach.
Recently, we have started an effort in this direction which
aims to collect small biopsy specimens of human tissue and
use the power of modern analytical techniques (‘omics’) to
identify putative mediators in these samples. The effects of
these candidates and their mechanism of action are then
pursued in animal studies. We recently published one test of
this approach54 using an experimental model of pain induced
by UVB irradiation. It is a common experience that sunburn
leads to a marked hyperalgesic state and much or all of this
is peripherally mediated.55 This model was chosen because it
can be implemented in both rats and humans. We took 3 mm
punch biopsies from normal and UVB skin in both species and
measured the levels of mRNA for a wide number of cytokines
and chemokines. The most upregulated factor was a chemo-
kine known as CXCL5. This factor, when injected into rodent
skin, recapitulates the sensory disturbances of sunburn and
blocking antibodies to CXCL5 given to UVB irradiated skin ame-
liorates the burn-associated sensory changes. We were, thus,
able to show that this novel factor contributes to the pain of
UVB irradiation.
Conclusion
The evidence we have presented here suggests that targeting
peripheral chemical mediators may be a fruitful avenue to
pursue in developing analgesic drugs. An important by-product
of this approach is the opportunity to avoid or minimize CNS
side-effects. What is less clear is how many important media-
tors there will be. Of course, the maximum benefit to patients is
likely to arise if there are relatively few mediators that partici-
pate in a wide range of painful conditions. However, the
limited data we already have (e.g. the different efficacy of
anti-TNFa and anti-NGF treatments) suggests that distinct
mediators may drive different pain states. The challenge
in this latter case will be to identify those different factors.
We believe the research strategy we have outlined will be bene-
ficial in this endeavour.
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